secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-09-21T20:10:47+00:00
Accession:  0001438533-26-000068
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brad Campbell named Travere CEO, succeeding Eric Dube effective Dec 1
---------------------------------------------------------------------

- Eric Dube steps down as Travere President/CEO and Director effective Dec 1, 2026, remaining Executive Advisor until Feb 15, 2027.
- Bradley Campbell (ex-CEO of Amicus until its Apr 2026 BioMarin acquisition) starts as President/CEO and Director on Dec 1, 2026.
- Campbell receives $1.0M base salary, 85% target bonus, $500k expense payment, and ~$16.5M initial equity (option + RSUs); ~$3.75M performance RSU in 2027.
- Dube keeps salary through Feb 2027, eligible for 75% 2026 bonus, but no 2027 bonus or new equity; performance RSUs cease vesting at separation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/0001438533-26-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/tvtx-20260921.htm
  HTML page:      https://secwatch.observer/filing/0001438533-26-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer